Evidence map›Paper›PMID 33481359›Full record

ArticleJournal of the International AIDS Society2021

Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities.

Gordon Mansergh, Krishna Kiran Kota, Rob Stephenson, Sabina Hirshfield, Patrick Sullivan

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Exploring Willingness to Use Long-Acting Injectable PrEP Among Sexual and Gender Minoritized People Accessing Pharmacies.AIDS education and prevention : official publication of the International Society for AIDS Education · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Gordon ManserghDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0002-3202-9081
Krishna Kiran KotaOak Ridge Institute for Science and Education, Oak Ridge, TN, USA.
Rob StephensonUniversity of Michigan, Ann Arbor, MI, USA.
Sabina HirshfieldSUNY Downstate Health Sciences University, Brooklyn, NYC, USA.
Patrick SullivanEmory University, Atlanta, GA, USA.ORCID 0000-0002-7728-0587
Centers for Disease Control and Prevention · USEmory University · USOak Ridge Associated Universities · USSUNY Downstate Health Sciences University · USUniversity of Michigan · US

Funding

Mobile Messaging Intervention to Present New HIV Prevention Options for MSMU01PS004977 · PS · EMORY UNIVERSITY · PI SULLIVAN, PATRICK SEAN · 2015 to 2018
$3.8M
ACL HHS U01PS004977NCHHSTP CDC HHS U01 PS004977
6 · The paper itself

Abstract

backgroundDaily oral pre-exposure prophylaxis (PrEP) is available and recommended for men who have sex with men (MSM) at risk for HIV infection. Other HIV prevention products are being developed, including long-acting injectable (LAI) and event-based oral and topical formulations. Understanding preferences for potential products by MSM can help direct further development of prevention messaging.

methodsWe present baseline data from HIV-negative participants enrolled in the US Mobile Messaging for Men (M-cubed) Study. Participants were asked their likelihood of and rank order preference for using daily oral PrEP and various potential prevention products (one- to -three-month injections, 2-1-1 sexual event oral dosing, anal or penile gel, or anal suppository), and their sociodemographic characteristics. Bivariate and multivariable logistics regression assessed demographic associations with likelihood of use and rank order preference.

resultsOverall, most MSM reported a likelihood of using LAI (74%), sexual event-based pills (67%) and penile gel (64%). Men who reported recent unprotected (condomless and PrEPless) anal sex most preferred a penile gel formulation (74%), followed closely by LAI and event-based pills (73% each). Current PrEP users (vs. non-users) had greater odds of reporting likelihood to use LAI (AOR = 3.29, 95% CI = 2.12 to 5.11), whereas men reporting recent unprotected anal sex had a greater odds of likelihood to use a penile gel (AOR = 1.79, 95% CI = 1.27 to 2.52) and an anal suppository (AOR = 1.48, 95% CI = 1.08 to 2.02). Hispanic/Latino (vs. White) MSM (AOR = 2.29, 95% CI = 1.40 to 3.73) and, marginally, Black MSM (AOR = 1.54, 95% CI = 1.00 to 2.38) had greater odds of reporting likelihood to use penile gel. Similar patterns were found for rank ordering preference of products, including condoms.

conclusionsMost MSM were interested in using various potential future HIV prevention products, especially LAI. However, two typologies of potential users emerged: men who prefer sexual event-based methods (condoms, event-based pill, sexual gels and suppositories) and men who prefer non-sexual event-based methods (daily pill, LAI). Men who reported recent unprotected anal sex preferred a penile gel product most, followed closely by sexual event-based pills and LAI. Racial/ethnic differences were noted as well. These findings on product preferences can help in formulation development and messaging.

Indexed as

Pre-Exposure ProphylaxisSexual and Gender MinoritiesAdultAnti-HIV AgentsBlack or African AmericanCondomsHIV InfectionsHomosexuality, MaleHumansMaleMiddle AgedSexual BehaviorYoung AdultAnti-HIV AgentsHIVmen who have sex with menMSMPrEPprevention methodsprevention productsprophylaxis

Identifiers

PMID33481359
PMCPMC7821953
OpenAlexW3123118159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.